ClinicalTrials.gg
CompletedNCT00383396Updated Feb 13, 2007

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

A Phase 4 interventional study of Topical Cyclosporine in Pterygia, sponsored by Innovative Medical. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2007-02-13.

Sponsored by Innovative Medical · Phase 4 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 12 studies in Pterygium with a site in United States — none open to participants now, 1 under way, 1 of them phase 3. Pterygium · United States.

Phase 4
4 of 12
none open now
Registered
1st of 12
by date
Lead sponsor
1 of 12
Innovative Medical

Among the 12 studies in Pterygium with a site in United States, this one is one of 4 in phase 4, and was the 1st registered.

Pterygium

109 studies on the registry are indexed under Pterygium; 9 are open to participants now.

Browse Pterygium studies →

Open to participants now

None of the 12 studies in Pterygium with a site in United States is open now. The open studies under Pterygium, anywhere →

Who these studies take

Of the 3 Pterygium studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pterygium with a site in United States as a file.
02

Study summary

To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

03

Conditions studied

  • Pterygia

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All

Eligibility criteria

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.
05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)

Interventions

06

Study locations

1 site
  • Dr. Schechter
    Boynton Beach, Florida 33426, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00383396
Lead sponsor
Innovative Medical
First posted
Oct 3, 2006
Last update
Feb 13, 2007

Study contacts

Barry Schechter, MD
principal investigator · Florida Eye Microsurgical Institute
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion